文献速递炎症性肠病

克罗恩病临床试验疗效与安全性终点的定义异质性:一项系统综述

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-03-27

该研究检索了截至2017年3月1日的安慰剂对照随机对照试验,纳入116项试验(81项诱导、44项维持、7项术后预防,共27263例患者),发现临床应答与缓解的定义多达38种、失应答定义32种,内镜与组织学终点定义亦不一致,作者认为需优选核心结局集以标准化疗效与安全性评价。

要点

  • 共纳入116项安慰剂对照随机对照试验,含27263例患者,最常见的疗效终点为克罗恩病活动指数评分。
  • 临床应答或缓解有38种独特定义,失应答有32种定义,内镜应答、缓解与愈合定义亦异质。
  • 组织学结局报告率在诱导试验为11.1%、维持试验为2.3%、术后预防试验为14.3%。

核心结论

  • 系统综述显示克罗恩病随机对照试验中应答与缓解的定义存在异质性,且报告结局随时间变化。
  • 作者认为优选一套核心结局集以标准化克罗恩病试验的疗效与安全性评价是优先事项。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE和Cochrane图书馆截至2017年3月1日的文献。
  • 纳入成人克罗恩病患者接受氨基水杨酸类、免疫调节剂、糖皮质激素、生物制剂和口服小分子药物的安慰剂对照随机对照试验。
  • 最终分析纳入116项随机对照试验(81项诱导、44项维持、7项术后预防试验),共27263例患者。

主要发现

  • 所有试验均报告临床疗效终点,最常见的终点为克罗恩病活动指数评分。
  • 共识别38种独特的临床应答或缓解定义和32种失应答定义。
  • 内镜应答、缓解和内镜愈合的定义亦异质,采用克罗恩病内镜严重程度指数、克罗恩病简化内镜评分、溃疡消退和Rutgeerts术后内镜评分评估。
  • 组织学结局报告率:诱导试验11.1%、维持试验2.3%、术后预防试验14.3%。
  • 生物标志物结局报告率:诱导试验81.5%、维持试验68.2%、术后预防试验42.9%;安全性结局报告率:诱导试验93.8%、维持试验97.7%、术后预防试验85.7%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endpoints in randomized controlled trials (RCTs) of Crohn's disease (CD) are changing. We performed a systematic review of efficacy and safety outcomes reported in placebo-controlled RCTs of patients with CD. METHODS: We searched the MEDLINE, EMBASE, and the Cochrane Library through March 1, 2017 for placebo-controlled RCTs of adult patients with CD treated with aminosalicylates, immunomodulators, corticosteroids, biologics, and oral small molecules. Efficacy and safety outcomes, definitions, and measurement tools were collected and stratified by decade of publication. RESULTS: Our final analysis included 116 RCTs (81 induction, 44 maintenance, 7 postoperative prevention trials, comprising 27,263 patients). Clinical efficacy endpoints were reported in all trials; the most common endpoint was CD activity index score. We identified 38 unique definitions of clinical response or remission and 32 definitions of loss of response. Definitions of endoscopic response, remission, and endoscopic healing were also heterogeneous, evaluated using the CD endoscopic index of severity, the simple endoscopic score for CD, ulcer resolution, and Rutgeerts' Score for postoperative endoscopic appearance. Histologic outcomes were reported in 11.1% of induction trials, 2.3% of maintenance trials, and 14.3% of postoperative prevention trials. Biomarker outcomes were reported in 81.5% induction trials, 68.2% of maintenance trials, and 42.9% of postoperative prevention trials. Safety outcomes were reported in 93.8% of induction trials, 97.7% of maintenance trials, and 85.7% of postoperative prevention trials. CONCLUSIONS: In this systematic review, we demonstrate heterogeneity in definitions of response and remission, and changes in outcomes reported in RCTs of CD. It is a priority to select a core set of outcomes to standardize efficacy and safety evaluation in trials of patients with CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ma C, Hussein IM, Al-Abbar YJ, et al. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018. PMID: 29596987. doi:10.1016/j.cgh.2018.02.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。